معرفی
Pradeep Nathan is an Affiliated Associate Professor in the Department of Psychiatry at the University of Cambridge's School of Clinical Medicine, and also holds positions as an Honorary Professor at King's College London and Adjunct Professor of Neuroscience at Monash University. He works full-time as Executive Director and Leader in Experimental Medicine at Neurocrine Biosciences Ltd.
His educational background includes pharmacology and neuroscience studies at the University of Melbourne, followed by a PhD in Experimental Medicine. His research focuses on neuropharmacology and neural substrates of cognition and emotion, as well as psychiatric and neurological endophenotypes. He utilizes cognitive, functional and molecular neuroimaging techniques including fMRI, electrophysiology, and PET to understand how neuropharmacological agents modulate cognitive and emotional processes and associated neural networks. His work also applies these approaches to CNS drug discovery through development of functional biomarkers for cognitive and emotional dysfunction in psychiatric and neurological disorders.
His recent publications demonstrate expertise in areas including Alzheimer's disease, schizophrenia, Parkinson's disease, and addiction, with particular focus on muscarinic M1 receptor agonists, orexin receptor antagonists, and other neuropharmacological targets for cognitive and emotional disorders. His research has resulted in over 180 publications with an H-index of 55 and 11,000 citations.
- Fellow of the American College of Neuropsychopharmacology
- Fellow of the American College of Clinical Pharmacology
Professor Nathan has over 15 years of experience in drug development, playing significant leadership roles in pre-clinical and clinical development for various CNS targets. He has contributed to medical sciences through scientific peer review and collaboration across industry/academia boundaries. He has served on MRC panels and been part of European-wide working groups addressing challenges in psychiatric drug development. His laboratory and research team focus on translational neuroscience and drug discovery/development, with particular emphasis on experimental medicine strategies for CNS disorders.
